Cardionomic is developing a transformative, neuromodulation treatment to address a large unmet need for patients suffering from acute decompensated heart failure (ADHF). The company’s catheter-based Cardiac Pulmonary Nerve Stimulation (CPNS) System electrically stimulates the autonomic cardiac nerves to increase contractility of the heart. Cardionomic has successfully demonstrated human feasibility of the physiological mechanism behind its device in multiple investigational clinical studies.
Company’s Keywords:
<24
<4420000
<2015